Premium
Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience
Author(s) -
Gemici Aliihsan,
Aydogdu Ismet,
Terzi Hatice,
Sencan Mehmet,
Aslan Alma,
Kaya Ali Hakan,
Dal Mehmet Sinan,
Akay Meltem Olga,
Dogu Mehmet Hilmi,
Ayyildiz Orhan,
Sahin Fahri,
Cagliyan Gulsum Akgun,
Yilmaz Mehmet,
Gokgoz Zafer,
Bilen Yusuf,
Demir Cengiz,
Sevindik Omur Gokmen,
Korkmaz Serdal,
Eser Bulent,
Altuntas Fevzi
Publication year - 2018
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2460
Subject(s) - medicine , chemoimmunotherapy , stage (stratigraphy) , refractory (planetary science) , chemotherapy , salvage therapy , lymphoma , surgery , progressive disease , cyclophosphamide , paleontology , physics , astrobiology , biology
Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty‐three patients were included in the study. Median age of patients was 37.5 years (18‐70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow‐up was 46 months. During follow‐up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12 months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46 months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses.